Sirtuin 7 promotes cellular survival following genomic stress by attenuation of DNA damage, SAPK activation and p53 response

Experimental Cell Research

Volumn 331, Issue 1, 2015, Pages 123-141

  Kiran, Shashi ^a   Oddi, Vineesha ^a   Ramakrishna, Gayatri ^a,b  

^a CENTRE FOR DNA FINGERPRINTING AND DIAGNOSTICS   (India)

^b INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

Author keywords

Cell cycle; Cell death; DNA damage; Doxorubicin; P53; Senescence; SIRT7

Indexed keywords

BIOLOGICAL MARKER; DOXORUBICIN; GREEN FLUORESCENT PROTEIN; HISTONE H2AX; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P21; PROTEIN P53; SIRTUIN 7; STRESS ACTIVATED PROTEIN KINASE; SIRT7 PROTEIN, HUMAN; SIRTUIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE 1;

3T3 CELL LINE; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; GENOMIC STRESS; NONHUMAN; NUCLEOLUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SENESCENCE; U2OS CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE TUMOR; CELL CYCLE; FLOW CYTOMETRY; GENETICS; GENOMIC INSTABILITY; HUMAN; METABOLISM; MOUSE; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

MAMMALIA;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; DNA DAMAGE; FLOW CYTOMETRY; GENOMIC INSTABILITY; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 8; NIH 3T3 CELLS; OSTEOSARCOMA; RNA, SMALL INTERFERING; SIRTUINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84921033108     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.11.001     Document Type: Article

References (52)

1. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 2003, 3:155-168.
2. Falck J., Coates J., Jackson S.P. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005, 434:605-611.
3. Craig A., Scott M., Burch L., Smith G., Ball K., Hupp T. Allosteric effects mediate CHK2 phosphorylation of the p53 transactivation domain. EMBO Rep. 2003, 4:787-792.
4. Donzelli M., Draetta G.F. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep. 2003, 4:671-677.
5. Falck J., Mailand N., Syljuasen R.G., Bartek J., Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001, 410:842-847.
6. Chen X., Ko L.J., Jayaraman L., Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 1996, 10:2438-2451.
7. Kracikova M., Akiri G., George A., Sachidanandam R., Aaronson S.A. A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ. 2013, 20:576-578.
8. Martin S.G., Laroche T., Suka N., Grunstein M., Gasser S.M. Relocalization of telomeric Ku and SIR proteins in response to DNA strand breaks in yeast. Cell 1999, 97:621-633.
9. McAinsh A.D., Scott-Drew S., Murray J.A., Jackson S.P. DNA damage triggers disruption of telomeric silencing and Mec1p-dependent relocation of Sir3p. Curr. Biol. 1999, 9:963-966.
10. Mills K.D., Sinclair D.A., Guarente L. MEC1-dependent redistribution of the Sir3 silencing protein from telomeres to DNA double-strand breaks. Cell 1999, 97:609-620.
11. Kaeberlein M., McVey M., Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 1999, 13:2570-2580.
12. Kawahara T.L., Michishita E., Adler A.S., Damian M., Berber E., Lin M., McCord R.A., Ongaigui K.C., Boxer L.D., Chang H.Y., Chua K.F. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 2009, 136:62-74.
13. Oberdoerffer P., Michan S., McVay M., Mostoslavsky R., Vann J., Park S.K., Hartlerode A., Stegmuller J., Hafner A., Loerch P., Wright S.M., Mills K.D., Bonni A., Yankner B.A., Scully R., Prolla T.A., Alt F.W., Sinclair D.A. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell 2008, 135:907-918.
14. Someya S., Yu W., Hallows W.C., Xu J., Vann J.M., Leeuwenburgh C., Tanokura M., Denu J.M., Prolla T.A. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 2010, 143:802-812.
15. Yamamori T., DeRicco J., Naqvi A., Hoffman T.A., Mattagajasingh I., Kasuno K., Jung S.B., Kim C.S., Irani K. SIRT1 deacetylates APE1 and regulates cellular base excision repair. Nucleic Acids Res. 2010, 38:832-845.
16. Barber M.F., Michishita-Kioi E., Xi Y., Tasselli L., Kioi M., Moqtaderi Z., Tennen R.I., Paredes S., Young N.L., Chen K., Struhl K., Garcia B.A., Gozani O., Li W., Chua K.F. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 2012, 487:114-118.
17. Ford E., Voit R., Liszt G., Magin C., Grummt I., Guarente L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev. 2006, 20:1075-1080.
18. Michishita E., Park J.Y., Burneskis J.M., Barrett J.C., Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell 2005, 16:4623-4635.
19. Mao Z., Hine C., Tian X., Van Meter M., Au M., Vaidya A., Seluanov A., Gorbunova V. SIRT6 promotes DNA repair under stress by activating PARP1. Science 2011, 332:1443-1446.
20. Vakhrusheva O., Braeuer D., Liu Z., Braun T., Bober E. Sirt7-dependent inhibition of cell growth and proliferation might be instrumental to mediate tissue integrity during aging. J. Physiol. Pharmacol. 2008, 9:201-212.
21. Grob A., Roussel P., Wright J.E., McStay B., Hernandez-Verdun D., Sirri V. Involvement of SIRT7 in resumption of rDNA transcription at the exit from mitosis. J. Cell Sci. 2009, 122:489-498.
22. Vakhrusheva O., Smolka C., Gajawada P., Kostin S., Boettger T., Kubin T., Braun T., Bober E. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ. Res. 2008, 102:703-710.
23. Shin J., He M., Liu Y., Paredes S., Villanova L., Brown K., Qiu X., Nabavi N., Mohrin M., Wojnoonski K., Li P., Cheng H.L., Murphy A.J., Valenzuela D.M., Luo H., Kapahi P., Krauss R., Mostoslavsky R., Yancopoulos G.D., Alt F.W., Chua K.F., Chen D. SIRT7 represses myc activity to suppress ER stress and prevent fatty liver disease. Cell Rep. 2013, 5:654-665.
24. Tsai Y.C., Greco T.M., Boonmee A., Miteva Y., Cristea I.M. Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription. Mol. Cell. Proteomics 2012, 11. (M111 015156).
25. Chen S., Seiler J., Santiago-Reichelt M., Felbel K., Grummt I., Voit R. Repression of RNA polymerase I upon stress ss caused by inhibition of RNA-dependent deacetylation of PAF53 by SIRT7. Mol. Cell 2013, 52:303-313.
26. Hubbi M.E., Hu H., Kshitiz D.M., Gilkes G.L., Semenza Sirtuin-7 Inhibits the activity of hypoxia-inducible factors. J. Biol. Chem. 2013, 288:20768-20775.
27. Tsai Y.C., Greco T.M., Cristea I.M. SIRT7 plays a role in ribosome biogenesis and protein synthesis. Mol. Cell. Proteomics 2013, 10:10.
28. Aljada A., Saleh A.M., Al Suwaidan S. Modulation of insulin/IGFs pathways by sirtuin-7 inhibition in drug-induced chemoreistance. Diagn. Pathol. 2014, 9:1746. (1596).
29. Yoshizawa T., Karim M.F., Sato Y., Senokuchi T., Miyata K., Fukuda T., Go C., Tasaki M., Uchimura K., Kadomatsu T., Tian Z., Smolka C., Sawa T., Takeya M., Tomizawa K., Ando Y., Araki E., Akaike T., Braun T., Oike Y., Bober E., Yamagata K. SIRT7 controls hepatic lipid metabolism by regulating the ubiquitin-proteasome pathway. Cell Metab. 2014, 19:712-721.
30. Kiran S., Chatterjee N., Singh S., Kaul S.C., Wadhwa R., Ramakrishna G. Intracellular distribution of human SIRT7 and mapping of the nuclear/nucleolar localization signal. FEBS J. 2013, 280:3451-3466.
31. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 1995, 92:9363-9367.
32. Bartek J., Lukas J. Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr. Opin. Cell Biol. 2001, 13:738-747.
33. Boe C.A., Krohn M., Rodland G.E., Capiaghi C., Maillard O., Thoma F., Boye E., Grallert B. Induction of a G1-S checkpoint in fission yeast. Proc. Natl. Acad. Sci. USA 2012, 109:9911-9916.
34. Tewey K.M., Rowe T.C., Yang L., Halligan B.D., Liu L.F., Adriamycin-induced D.N.A. damage mediated by mammalian DNA topoisomerase II. Science 1984, 226:466-468.
35. Chang B.D., Xuan Y., Broude E.V., Zhu H., Schott B., Fang J., Roninson I.B. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 1999, 18:4808-4818.
36. Eom Y.W., Kim M.A., Park S.S., Goo M.J., Kwon H.J., Sohn S., Kim W.H., Yoon G., Choi K.S. Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 2005, 24:4765-4777.
37. Lee E.R., Kim J.Y., Kang Y.J., Ahn J.Y., Kim J.H., Kim B.W., Choi H.Y., Jeong M.Y., Cho S.G. Interplay between PI3K/Akt and MAPK signaling pathways in DNA-damaging drug-induced apoptosis. Biochim. Biophys. Acta 2006, 9:958-968.
38. Brantley-Finley C., Lyle C.S., Du L., Goodwin M.E., Hall T., Szwedo D., Kaushal G.P., Chambers T.C. The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide. Biochem. Pharmacol. 2003, 66:459-469.
39. Hazzalin C.A., Le Panse R., Cano E., Mahadevan L.C. Anisomycin selectively desensitizes signalling components involved in stress kinase activation and fos and jun induction. Mol. Cell. Biol. 1998, 18:1844-1854.
40. Sakaguchi K., Herrera J.E., Saito S., Miki T., Bustin M., Vassilev A., Anderson C.W., Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 1998, 12:2831-2841.
41. Shinohara T., Uesugi M. In-vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Tanpakushitsu Kakusan Koso 2007, 52:1816-1817.
42. Han Y., Liu Y., Zhang H., Wang T., Diao R., Jiang Z., Gui Y., Cai Z. Hsa-miR-125b suppresses bladder cancer development by down-regulating oncogene SIRT7 and oncogenic long non-coding RNA MALAT1. FEBS Lett. 2013, 587:3875-3882.
43. Kim J.K., Noh J.H., Jung K.H., Eun J.W., Bae H.J., Kim M.G., Chang Y.G., Shen Q., Park W.S., Lee J.Y., Borlak J., Nam S.W. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology 2013, 57:1055-1067.
44. Hartwell L.H., Weinert T.A. Checkpoints: controls that ensure the order of cell cycle events. Science 1989, 246:629-634.
45. Tvegard T., Soltani H., Skjolberg H.C., Krohn M., Nilssen E.A., Kearsey S.E., Grallert B., Boye E. A novel checkpoint mechanism regulating the G1/S transition. Genes Dev. 2007, 21:649-654.
46. Fritz G., Kaina B. Activation of c-Jun N-terminal kinase 1 by UV irradiation is inhibited by wortmannin without affecting c-iun expression. Mol. Cell. Biol. 1999, 19:1768-1774.
47. Chen X., Chen J., Gan S., Guan H., Zhou Y., Ouyang Q., Shi J. DNA damage strength modulates a bimodal switch of p53 dynamics for cell-fate control. BMC Biol. 2013, 11:1741-7007.
48. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005, 120:513-522.
49. Macip S., Igarashi M., Berggren P., Yu J., Lee S.W., Aaronson S.A. Influence of induced reactive oxygen species in p53-mediated cell fate decisions. Mol. Cell. Biol. 2003, 23:8576-8585.
50. Fernandez-Cuesta L., Anaganti S., Hainaut P., Olivier M. Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines. Breast Cancer Res. Treat. 2011, 125:35-42.
51. Cheng Y., Qiu F., Tashiro S., Onodera S., Ikejima T. ERK and JNK mediate TNFalpha-induced p53 activation in apoptotic and autophagic L929 cell death. Biochem. Biophys. Res. Commun. 2008, 376:483-488.
52. Fuchs S.Y., Adler V., Pincus M.R., Ronai Z. MEKK1/JNK signaling stabilizes and activates p53. Proc. Natl. Acad. Sci. USA 1998, 95:10541-10546.